<?xml version="1.0" encoding="UTF-8"?>
<p id="par0195">Recently, the American Thoracic Society has released interim guidance on treating COVID-19. For hospitalized patients with pneumonia, HCQ and CQ may be used on a case-by-case basis, but clinicians must consider the potential benefit/risk ratio and the patient's condition must be severe. For outpatients with COVID-19 or hospitalized patients without pneumonia there are no specific recommendations [
 <xref rid="bib0330" ref-type="bibr">66</xref>]. In contrast, the Surviving Sepsis Campaign announced that thereâ€™s insufficient evidence to declare a recommendation on the use of CQ and HCQ in critically ill adults with COVID-19 [
 <xref rid="bib0335" ref-type="bibr">67</xref>]. The Infectious Diseases Society of America (IDSA), on the other hand, in its recently published guidelines [
 <xref rid="bib0340" ref-type="bibr">68</xref>] has recommended HCQ/CQ (+/-azithromycin) in the context of clinical trials only.
</p>
